TABLE 2.

Lung CFU counts from the second experiment

Drug regimenaMean lung log10 CFU counts ± SD at the indicated time pointsb
D0W2W4W8
Controls
    Untreated7.09 ± 0.168.05 ± 0.17c
    INH3.1256.90 ± 0.156.59 ± 0.126.03 ± 0.20
    INH12.56.50 ± 0.205.75 ± 0.274.84 ± 0.14
    INH506.29 ± 0.255.23 ± 0.134.51 ± 0.09
    RIF6.90 ± 0.085.75 ± 0.334.57 ± 0.30
    PZA7.62 ± 0.075.93 ± 0.334.72 ± 0.69
Tests
    RIF-PZA6.46 ± 0.134.32 ± 0.151.41 ± 0.49
    RIF+INH3.1256.25 ± 0.255.30 ± 0.463.95 ± 0.14
    RIF+INH12.56.19 ± 0.255.00 ± 0.193.06 ± 0.24
    RIF+INH506.17 ± 0.225.04 ± 0.202.84 ± 0.27
    PZA+INH3.1256.85 ± 0.125.51 ± 0.264.22 ± 0.19
    PZA+INH12.56.74 ± 0.065.93 ± 0.185.08 ± 0.21
    PZA+INH506.45 ± 0.315.75 ± 0.224.83 ± 0.17
  • a Drugs and doses: rifampin (RIF), 10 mg/kg; pyrazinamide (PZA), 150 mg/kg; isoniazid (INH), dose in mg/kg indicated by subscripted numbers.

  • b W, week.

  • c CFU counts from the remaining 5/13 control mice.